 |
Biosketch
Name: David Andes
Education
1984-88 Undergraduate:St. Louis University,BA Biology
1988-92 Medical School: University of Missouri, Columbia
1992-95 Residency Training: University of Wisconsin, Madison, Internal Medicine
1995-96 Chief Residency:University of Wisconsin, Madison, Internal Medicine
1996-99 Clinical Fellowship: University of Wisconsin, Madison, Infectious Disease
1999-2001 Research Training: Antimicrobial Pharmacodynamics – Mentor: William Craig
1999-2001 Research Training: Molecular Biology/Mycology – Mentors: Bernard Weisblum/Bruce Klein
2002 Marine Biological Laboratory, Wood’s Hole – Molecular Mycology
Positions and Appointments
1999-2002 University of Wisconsin, Madison, Assistant Professor (CHS), Department of Medicine, Section of Infectious Diseases
2002-present University of Wisconsin, Madison, Assistant Professor (Tenure Track), Department of Medicine, Section of Infectious Diseases
2003-present University of Wisconsin, Madison, Assistant Professor
Department of Medical Microbiology and Immunology
2006-present Infectious Diseases Fellowship Director
2007-present Associate Professor with Tenure, University of Wisconsin, Department of Medicine and Medical Microbiology and
Immunology
Honors and Awards:
1994 American College of Physicians Clinical Award
1995-96 Chief Medicine Resident
1995-96 Department of Medicine Teacher of the Year Award
1998 George McCracken Research Fellow Award
2001 National Institutes of Health Mentored Clinical Scientist Development Award
2002 . Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) – Young Investigator Award
2003 International Society for Human and Animal Mycology – Poster Prize “President’s Dozen”
2003 Mentor for Fellow-in-training Infectious Diseases Society of America Research Special Citation
2004 Selected Top 10 Mycology Poster Presentation Infectious Diseases Society of America Annual Meeting 2004
2005 Mentor for Fellow-in-training Infectious Diseases Society of America Research Special Citation
2006 . Invited Faculty – Molecular Mycology Course, Marine Biological Institute, Woods Hole, MA
2006 Selected Infectious Diseases Society of America – Candidiasis Treatment Guideline Committee
2006 Puestow Award – Young Investigator Basic Science Research, University of Wisconsin, Dept of Medicine
2006 Elected President – International Society of Antimicrobial Pharmacology
2007 Selected Voting Member – Clinical Laboratory Standards Institute – Antifungal Testing Committee
2007 Selected American Academy of Otolaryngology, Head and Neck Surgery – Sinusitis Guideline Committee
Professional Societies
1. Mycosis Study Group
2. Infectious Diseases Society of America
3. American Society for Microbiology
4. International Society of Antimicrobial Pharmacology – Treasurer 2002- 2006, President-Elect 2006
4. American College of Physicians
5. European Society of Clinical Microbiology and Infectious Diseases
6. American Association for the Advancement of Science
8 Central Society for Clinical Research
Teaching Activities
Undergraduate
Years Course Title Director Role Students Time
1998-present MMI410 Medical Mycology Jon Woods and Joanne Weber Lecturer and Honors project mentor
Lecture titles:
1. Antifungal therapy
2. Fungal diagnosis
3. Candida -Clinical
4. Candida - Pathogenesis 50-70 1 h lecture 4 times per year, 20 h per year honor project
Graduate School
Years Course Title Director Role Students Time
1999-present MMI504 Infectious Diseases Janet Shraeder Lecturer
Lecture titles:
1. Fungal infections 50-70 1 h lecture 1 time per year
2005-present MMM655 Biology and Genetics of Fungi Nancy Keller Lecturer
Lecture titles:
1. Candida - clinical
2. Candida - pathogenesis 20-30 1 h lecture 2 times per year
2006-present MMI773 Jon Woods and Jay Bangs Lecturer
Lecture title: Candida biofilms and drug resistance 20 1 h lecture 1 time per year
Medical Students
Years Course Title Director Role Students Time
1994-1996 Clinical Medicine and Practice NA Discussant of multiple clinical topics 3-5 1 h per week for 1 semester
1996-2001 3rd year mentor – internal medicine Elizabeth Silverman Discussant of multiple clinical topics 5 10 h per week for 1 month per year
1997-present MMI701-702 George Mejicano and Julie Franz Small group discussant of multiple topics 20 1-2 h up to 6 times per year
2001-present Pharmacology 727 Mike Seivert Lecturer
Lecture titles:
1. Antifungals 1
2. Antifungals 2
3. Clinical antivirals 150 1 h per lecture 3 times per year
2001-present Senior Therapeutics George Mejicano and Sue Morschauser Lecturer:
Lecture title:
Antifungal therapy 20-50 1 h lecture 1 time per year
2006-present Infection and Immunity Rich Proctor Lecturer:
Lecture titles
1. Antifungal drug resistance 20 2 h lecture 1 time per year
1999-present Infectious Diseases Clinical Service NA Bedside teaching and daily didactic sessions 1-2 per two week session 4-5 two week blocks, 1 h per day didactic, 3-4 h per day bedside teaching
Resident and Fellows
Years Course Title Director Role Students Time
1994-1995 Internal Medicine Morning Report Bennett Vogelman Discussant of multiple clinical topics 75 1 h per day for 200 days
1999-present Infectious diseases fellowship curriculum Dennis Maki 1999-2005, David Andes 2006 - present Lecturer
Titles: 1. antifungal therapy, 2. fungal diagnosis, 3. candidiasis, 4. aspergillosis, 5. outpatient mycology, 6. histoplasmosis, 7. vulvovaginal candidiasis, 8. antifungal prophylaxis and febrile neutropenia, 9. asymptomatic bacteriuria, 10. bacterial meningitis, 11. intra-abdominal infections 4 1 h up to 11 times per year
1999-present Infectious disease fellowship Dennis Maki 1999-2005, David Andes 2006 - present Clinical bedside teaching 3-5 2-4 h per day up to 9 weeks per year
1997-present Internal Medicine Tissue Conference Medicine chief resident Discussant; Topics: 1. tuberculosis meningitis 1997, 2. septic thrombosis 1997, 3. erhlichiosis 1998, 4. hematologic diagnosis of infection 1998, 5. candidiasis 1998, histoplasmosis 2001, fungal brain abscess 2003 30-50 1 h each topic
2004-present Infection diseases fellowship Dennis Maki 1999-2005, David Andes 2006 - present Create and update web-based curriculum Multiple 200 h initial, 40 h per year since
2005-2006 Internal Medicine Resident Career Week Bennett Vogelman Lecturer: topics 1. finding your nitch, 2. time management 20-75 1 h each
1999-present Infectious Diseases Clinical Service NA Bedside teaching and daily didactic sessions 1-2 per two week session 4-5 two week blocks, 1 h per day didactic, 3-4 h per day bedside teaching
*Infectious Disease Section Web Curriculum
http://www.medicine.wisc.edu/mainweb/DOMPages.php?section=infectiousdisease&page=infectiousdiseasemain
Continuing Medical Education
Years Course Title Lecture Location Students Time
1999 University of Wisconsin Grand Rounds Community-acquired pneumonia University of Wisconsin 100 1 h
University of Wisconsin Radio Lecture Community-acquired pneumonia University of Wisconsin unknown 1 h
Meriter Hospital Grand Rounds Community-acquired pneumonia Meriter Hospital, Madison, WI 50 1 h
University of Wisconsin - Update in Infectious Diseases Antifungal therapy Madison 200 1 h
University of Wisconsin - Update in Infectious Diseases Community-acquired pneumonia Madison 200 1 h
2000 Wisconsin Infectious Diseases Society of America Community-acquired pneumonia Madison 30 1 h
University of Wisconsin Website lecture Antifungal therapy University of Wisconsin unknown 1 h
2001 University of Wisconsin Pulmonary Grand Rounds Invasive aspergillosis University of Wisconsin 20-30 1 h
Sinusitis Update Customizing Antibiotic Therapy of Sinusitis: Use of Pharmacodynamics Coral Gables, FL 50 1 h
Infectious Diseases Society, University of Wisconsin, Lacrosse Systemic antifungal therapy University of Wisconsin Lacrosse, WI 30 1 h
University of Wisconsin – Lacrosse
Internal Medicine Resident Conferene Nosocomial candidiasis University of Wisconsin, Lacrosse, WI 50 1 h
University of Wisconsin - Update in Infectious Diseases Outpatient fungal infection management University of Wisconsin 200 1 h
University of Wisconsin - Update in Infectious Diseases Management of Upper respiratory tract infections University of Wisconsin 200 1 h
University of Wisconsin Grand Rounds Community-acquired pneumonia University of Wisconsin 100 1 h
2002 University of Wisconsin Dept of Medicine Grand Rounds Management of chronic sinusitis University of Wisconsin 100 1 h
University of Wisconsin Transplant Grand Rounds Advances in systemic antifungal therapy University of Wisconsin 50 1 h
National webcast Advances in management of sinusitis in the era of antibiotic resistance – pharmacodynamic impact unknown 1 h
2003 Meriter Hospital Grand Rounds Advances in management of acute and chronic rhinosinusitis Meriter Hospital, Madison, WI 50 1 h
Regional CME Advances in management of otitis media in an era of antibiotic resistance Minneapolis, MN 30 1 h
University of Wisconsin – Lacrosse
Internal Medicine Grand Rounds Advances in the epidemiology and therapy of fungal infections. University of Wisconsin, Lacrosse, WI 50 1 h
University of Wisconsin – Surgery /Trauma Grand Rounds Candidiasis in the surgical intensive care unit University of Wisconsin 30 1 h
2004 University of Wisconsin - Update in Infectious Diseases Fungal infections – frequently asked questions University of Wisconsin 200 1 h
University of Wisconsin - Update in Infectious Diseases Management of upper respiratory tract infection University of Wisconsin 200 1 h
University of Wisconsin Medical Grand Rounds Fungal infections – frequently asked questions University of Wisconsin 100 1 h
2005 Gunderson Clinic Medical Grand Rounds Fungal infections – frequently asked questions Gunderson Clinic 40 1 h
University of Wisconsin - Update in Infectious Diseases Community-acquired pneumonia University of Wisconsin 50 1 h
University of Wisconsin - Update in Infectious Diseases Antifungal update University of Wisconsin 50 1 h
2006 University of Wisconsin Pulmonary Grand Rounds Candidemia University of Wisconsin 50 1 h
Medical College of Wisconsin Transplant Grand Rounds Antifungal therapy Medical College of Wisconsin, Milwaukee, WI 20 1 h
Visiting Professor
Years Location
2005 Gunderson Clinic – Lacrosse, WI
2006 Albert Einstein School of Medicine, NY
2006 University of Alabama - Birmingham
2006 University of California – Los Angeles
2007 Ordway Research Institute – Albany, NY
2007 Cornell – Sloan Kettering
2007 State Serum Institute – Copenhagen, Denmark
Research Mentor
Infectious Disease Fellows
Sue Wang 2001
John Christianson 2001
Jeannina Smith 2002-2005
Wendy Slattery 2003-2004
Nasia Safdar
Shravan Kethireddy 2007
Medical Students and Residents
Alex Lepak 2002-2003
Jason Clark Summer 2002
Jeniel Nett – 2003 – Internal Medicine Resident
Kristie Vujnovich
Colleen Sherkow - 2006 NIH/GCRC Shapiro award
Casey Herreforth - 2006 NIH/GCRC Shapiro award
Graduate Students
Jeniel Nett (Cellular and Molecular Biology/Hematology T32))
Postdoctoral Student
Robyn Perrin (Department of Plant Pathology)
Graduate/Postgraduate Training Programs
2005-present Trainer: Microbiology Doctoral Training Program
2005-present Trainer: Kirschstein National Research Service Award - (NIH National Heart, Lung, and Blood Institute Grant: T32 HL07899)
2005-present Trainer: Cellular and Molecular Biology Program
Undergraduate
Jonathan Wong, 2006 Research honors
Kathleen Holoyda, 2006 Mycology research honors
Brian Hoff, 2005 Biology 152
Megan Hichwa, 2006 Biology 152
Lane Benes, 2007 Biology 152
Thesis Committee Member
1. DaWoon Chung – Nancy Keller mentor (Plant Pathology)
2. Spencer Hoover – Rob Stricker mentor (Medical Microbiology)
3. Fang Li – Sean Palecek mentor (School of Engineering)
4. Greg Gauthier NIH Career Development Mentor Committee – Bruce Klein mentor
Published Peer Reviewed
1. Craig WA, Andes D. Oral versus parenteral antibiotic therapy. Med Clin of North Amer. 1995;79:479-509.
2. Craig WA, Andes D. Pharmacokinetics and pharmacodynamics of antibiotics in otitis media. Pediatr Infect Dis J. 1996;115:255-259.
3. Craig WA, Andes D. Aminoglycosides are useful for severe respiratory tract infections. Seminars in Resp Infect. 1997;12:271-277Andes D, Craig WA. Pharmacokinetics of fluoroquinolones in experimental endocarditis. Clin Infect Dis. 1998;27:47-50.
4. Andes D., Craig W.A. Pharmacokinetics and pharmacodynamics of outpatient intravenous antimicrobial therapy. Infect Dis Clinics North Am 1998;12:849-859.
5. Andes D, Craig WA. In-vivo activity of amoxicillin and amoxicillin/clavulanate against penicillin-resistant pneumococci in a murine thigh infection model. Antimicrob Agents Chemother. 1998;42:2375-2379.
6. Andes D, Urban A, Acher CW, Maki DG. Report of septic thrombosis from a PICC and review. Amer J Med. 1998;105:446-450
7. Andes D, van Ogtrop ML. Characterization and quantitation of the pharmacodynamics of fluconazole in a
neutropenic murine model of disseminated candidiasis model. Antimicrob Agents Chemother. 1999;43:2116-
2120.
8. Andes D, Craig WA. Pharmacokinetics and pharmacodynamics of antibiotics in meningitis. Infect Dis Clinics North Am 1999;13:595-617.
9. Andes D. Preclinical review of L-084, a new carbapenem. Current Opinion in Anti-infective Investigational Drugs. 1999;1:101-103
10. Andes D. Preclinical review of J-111225. Current Opinion in Anti-infective investigational Drugs. 1999;1:111-113.
11. Mouton JW, van Ogtrop ML, Andes D, Craig WA. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother. 1999;43:2473-2478.
12. Andes D, van Ogtrop ML. In-vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine candidiasis model. Antimicrob Agents Chemother. 2000;44:938-942.
13. van Ogtrop ML, Andes D, Stamstad TJ, Conklin B, Weiss WJ, Craig WA, Vesga O. In-vivo pharmacodynamic activity of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria. Antimicrob Agents Chemother. 2000;44:943:949.
14. Andes D, Bush R, Pasic T, Proctor R. Report of successful therapy with prolonged antifungal therapy of refractory allergic fungal sinusitis. Clin Infect Dis. 2000;31:202-4.
15. Andes D. In-vivo pharmacodynamics of amphotericin B against selected Candida species. Antimicrob Agents Chemother 2001;45:922-926.
16. Drusano GL, Preston S, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA. Use of preclinical data for selection of a phase II-III dose for everninomycin and identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001;45:13-22.
17. Andes D. Pharmacokinetic and pharmacodynamic properties of antimicrobials in the therapy of respiratory tract infections. Curr Opin Infect Dis. 2001;14:165-172.
18. Andes D, Craig WA. Characterization of the Pharmacodynamics of the New Fluoroquinolone, Gatifloxacin, in Murine Thigh and Lung Infection Models. Antimicrob Agents Chemother 2002;46:1665-1670.
19. Andes D., Craig, W.A. A Critical Review of Animal Model Pharmacokinetics and pharmacodynamics. International Journal of Antimicrobial Agents. 2002;19:261-268.
20. Andes D, Peng J, Craig WA. In-vivo characterization of the pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother. 2002;46:3484-3489.
21. Jones R, Andes D, Mandell L, Gothelf S, Ehrhardt A, Nicholson S. Gatifloxacin used for therapy of outpatient community-acquired pneumonia caused by Streptococcus pneumoniae. Diagn Microbiol Infect Dis. 2002;44:
22. Crnich C, Andes D. Molecular characterization of community-acquired Pseudomonas aeruginosa pneumonia. Clin Infect Dis. 2003;36:55-7.
23. Andes, D. Pharmacokinetics and pharmacodynamics in the development
of antifungal compounds. Current Opinion in Investigational Drugs 2003:4:991
8.
24. Andes, D. Clinical pharmacodynamics of antifungals. Infect Dis Clin N Amer. 2003;17:635-49.
25. Andes D, Marchillo K, Lowther, J., Bryskier, A., Stamstad, T., Conklin, R. In vivo pharmacodynamics of HMR 3270, a glucan-synthase inhibitor, in a murine candidiasis model. Antimicrob Agents Chemother. 2003;47:1187-1192.
26. Andes D, Marchillo, K., Stamstad, T., Conklin, R. In-vivo pharmacodynamics of a new triazole, ravuconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 2003;47:1193-1199.
27. Andes D. In-vivo pharmacodynamics of antifungal drugs in treatment of candidiasis. Antimicrob. Agents Chemother. 2003;47:1179-1186.
28. Christianson JC, Andes D. Primary cutaneous cryptococcosis: case report and review of the literature. Medical Mycology. 2003;41:177-188.
29. Safdar N, Young, DK, Andes D. Autochthonous furuncular myiasis in the United States: case report and literature review. Clin Infect Dis. 2003;36:73-80.
30. Adams M., Andes D., Kwon G. Amphotericin B encapsulated in micelles based on poly (ethylene oxide) – block – poly (L-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity. Biomacromolecules. 2003:4:750-757.
31. Andes D., Craig WA. Characterization of the pharmacodynamics of the new des-F(6) quinolone, garenoxacin (BMS 284756) in a murine thigh infection model. Antimicrob Agents Chemother. 2003;47:3935-3941
32. Andes D., Marchillo K, Conklin R. In vivo characterization of the pharmacodynamics of voriconazole in a murine model of disseminated candidiasis. Antimicrob. Agents Chemother. 2003:47:3165-9
33. Safdar N, Andes D, Craig WA. In-vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother. 2004;48:63-8.
34. Andes D. Clinical Utility of Antifungal Pharmacokinetics and Pharmacodynamics. Curr Opin Infect Dis 2004:17;533-40.
35. Andes D. Antifungal pharmacokinetics and pharmacodynamics: understanding the implications for antifungal drug resistance. Drug Resistance Updates. 2004;7:185-194
36. Andes D., Marchillo K, Stamstad T., Conklin R. Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis. Antimicrob Agents Chemother. 2004;48:137-42.
37. Agger W., Andes D, Burgess JW. Exophiala jeanselmei infection in a heart transplant recipient successfully treated with oral terbinafine. Clin Infect Dis 2004;38:e112-115.
38. Andes D., Anon J, Jacobs MR, Craig WA. Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections. Clin Lab Med 2004;24:477-502.
39. Andes D, J Nett, P. Oschel, R. Albrecht, K. Marchillo, A. Pitula. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun. 2004;72:6023-6031
40. Ulijasz AT, D Andes, JD Glasner, B Weisblum. Regulation of iron uptake and oxidative stress responses in Streptococcus pneumoniae by RitR, an orphan response regulator. J Bacteriol. 2004;186:8123-36.
41. Safdar N, Slattery WR, V Knasinski, RE Gangnon, JD Pirsch, D Andes. Epidemiology, risk factors, and outcome of candiduria in renal transplant recipients: a nested case-control study. Clin Infect Dis. 2005;15;:1413-21.
42. Andes D, Woods JP, Mejicano G. Meeting Report: Fungal Pathogenesis: Bridging the Gap Between the Bedside and the Bench. Mycopathologia 2005;159:2-6.
43. Andes D. Use of an animal model of disseminated candidiasis in the evaluation of antifungal therapy. Methods Mol Med. 2005;118:111-28.
44. Andes D, Safdar N. Efficacy of Micafungin for the Treatment of
Candidemia. Eur J Clin Microbiol Infect Dis. 2005;25;:1-3
45. Bhavnani SM, D Andes. Gemifloxacin in the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics-pharmacodynamics, clinical efficacy, and safety. Pharmacotherapy.2005;25:717-40.
46. Andes, D., Lepak, A., Pitula, A., Weisblum, B. Measurement of fungal transcriptional profile in a mammalian infection model. J. Infect Dis 2005;192:893-900.
47. Bok JW, Balajee SA, Marr KA, Andes D, Nielsen FJ, Frisvad JC, Keller NP. LaeA, a regulator of morphogenetic fungal virulence factors. Euk Cell. 2005;4:1574-82.
48. Gauthier G, Nork TM, Prince R, Andes D. Subtherapeutic Ocular Penetration of Caspofungin and Associated Treatment Failure in Candida albicans Endophthalmitis. Clin Infect Dis 2005;41:27-8.
49. Cirz RT, Chin JK, Andes D, Crecy-Lagard, Craig WA, Romesberg FE. Inhibition of mutation and combating the evolution of antibiotic resistance. PLOS Biology. 2005;3:176.
50. Tsitsigiannis DI, Bok JW, Andes D, Nielsen KF, Frisvad JC, Keller NP. Aspergillus cyclooxygenase-like enzymes are associated with prostaglandin production and virulence. Infect Immun. 2005;73:4548-59.
51. Andes D., Craig WA. Treatment of ESBL Producing Organisms: Pharmacokinetic and Pharmacodynamic Considerations. Clin Microbiol Infect 2005;11:10-17.
52. Nett J, Andes D. Imaging of the development and therapeutic response of
an in vivo fungal catheter biofilm. Microbiology Today 2005;13.1-2.
53. Andes D., Safdar N. Pharmacokinetic-Pharmacodynamic Comparison of Amphotericin B (AMB) and Two Lipid-Associated AMB Preparations, Liposomal AMB and AMB Lipid Complex, in Murine Candidiasis Models.Antimicrob Agents Chemother 2006; 50:674-84
54. Smith J, Andes D. Tissue penetration of antifungal drugs: implications for
drug selection: Methodology, Similarities, Differences, Relevance. Infections in
Medicine 2006;28:328-33.
55. Smith J, Safdar N, Knasinski V, Andes D. Voriconazole therapeutic drug monitoring – outcome analysis from a tertiary care center. Antimicrob Agents Chemother 2006;50:1570-2.
56. Andes, D., Forrest A, Lepak, A., Nett, J., Smith, J., Marchillo, K., Pitula, A., Impact of Antimicrobial Dosing Regimen on Evolution of Drug Resistance In Vivo: Fluconazole and Candida albicans. Antimicrob Agents Chemother. 2006 ;50:2374-83.
57. Andes D, Craig WA. Characterization of the Pharmacodynamics of a New Streptogramin, XRP 2868, in the Murine Thigh and Lung Infection Models. Antimicrob Agents Chemother 2006;50:243-9.
58. Pappas PG, Andes D, Schuster M, Hadley S, Rabkin J, Merion RM, Kauffman CA, Huckbee C, Dismukes WE, Karchmer AW. Invasive fungal infections in low risk liver transplant recipients: a multicenter prospective observational study. Amer J Transplant 2006;6:386-91.
59. Lepak A, L Lincoln, K. Marchillo, Andes D. Time Course Microbiologic Outcome and Gene Expression During and Following Fluconazole Exposure In vitro and In vivo. Antimicrob Agents Chemother. 2006;50:1311-9.
60. M.A. Pfaller, D.J. Diekema, J.H. Rex, A. Espinel-Ingroff, E.M. Johnson , D. Andes M.A. Ghannoum, , F.C. Odds, M.G. Rinaldi, D.J. Sheehan, L. Steele-Moore, P. Troke, T.J. Walsh, and D.J. Warnock. Correlation of MIC with Outcome for Candida Species Tested Against Voriconazole:Analysis and Proposal for Interpretive Breakpoints. J Clin Microbiol 2006;44:819-26.
61. Andes D, Craig W. Pharmacodynamics of a New MRSA Active Cephalosporin, PPI-0903 (TAK-599), in the Murine Thigh and Lung Infection Models – Identification of an In vivo PK/PD Target. Antimicrob Agents
Chemother. 2006;50:1376-83.
62. Andes D, Marchillo K, Nett J, Pitula A, Smith J. In Vivo Fluconazole Pharmacodynamics and Resistance Development in a Previously Susceptible Candida albicans Population Examined by Microbiologic and Transcriptional Profiling. Antimicrob Agents Chemother. 2006;50:2384-94.
63. Nobile CJ, Andes D, Nett J, Filler S, Mitchell AP. The Candida albicans transcription factor Bcr1p governs biofilm development in vitro and in vivo by activation of ALS3. PLoS Pathogens 2006;
64. Bok JW, Chung D, Balajee SA, Marr KA, Andes D, Nielsen KF, Frisvad JC, Keller NP. GliZ, a transcriptional regulator of gliotoxin biosynthesis, contributes to Aspergillus fumigatus virulence. Infect Immun.2006;74:6761-68.
65. Nobile CJ, Nett JE, Andes D, Mitchell AP. Function of C. albicans adhesion Hwp1 in biofilm formation. Euk Cell 2006;5:1604-1610.
66. Mukherjee PK, Mohamed S, Chandra J, Kuhn D, Liu S, Antar OS, Munyon R, Mitchell AP, Andes D, Chance MR, Rouabhia M, Ghannoum MA. Alcohol dehydrodenase restricts the ability of the pathogen Candida albicans to form a biofilm on catheter surfaces through an ethanol-based mechanism. Infect Immun. 2006;74:3804-16.
67. Nett J, Andes D. Candida albicans Biofilm Development, Modeling of a
Host Pathogen Interaction. Curr Opin Microbiol. 2006;9:1-6.
68. Dodds AES, Lewis RE, Lewis JS, Martin C, Andes D. Clinical
pharmacology of antifungals. Clin Infect Dis 2006;43:28-39.
69. Andes D. Clinical Antifungal Pharmacokinetics and Pharmacodynamics.
Infect Dis Clin N Amer 2006;30 :679-97.
70. Gauthier G, Safdar N, Andes D. Blastomycosis in solid organ transplant recipients. Transplant Infect Dis 2007;
71. Nett J, Lincoln L, Marchillo K, Van Handel M, Andes D. Role of Beta 1,3 glucan in Candida albicans biofilm resistance to fluconazole and amphotericin B. Antimicrob Agents Chemother. 2007;51:510-520.
72. Nett J, Lincoln L, Andes D. Use of secreted Beta 1,3 glucan to diagnose Candida catheter biofilm infections. J Infect Dis. 2007;195:1705-12.
73. Fang L, Wagner J, Marchillo K, Oshel P, Andes D, Palecek S. EAP1 enhances Candida albicans adhesion and in vivo biofilm formation. Euk Cell in press
74. Croy SR, Andes D, Kwon GS. Cremophor EL and polysorbate 80 attenuate nystatin induced toxicities and enhance potency in vitro. submitted
75. LaPlante KL, Rybak MJ, Andes D, Craig WA. Activity of clindamycin inducible community associated methicillin resistant Staphylococcus aureus versus daptomycin, clindamycin, doxycycline, linezolid in in vitro and in vivo pharmacodynamic models. Antimicrob Agents Chemother in press
76. Andes D, Craig WA. In vivo pharmacodynamic characterization of the new lipoglycopeptide, dalbavancin. Antimicrob Agents Chemother. 2007;51:1633-42.
77. Nett J, Lincoln L, Lepak L, Marchillo K, Andes D. Global transcriptional profile of Candida albicans in an in vivo central venous catheter model. submitted
78. Smith J, Safdar N, Knasinski V, Andes D. Impact of the campath on infection in solid organ transplantation – a case controlled study. Accepted with revisions
Book Chapters
1. Andes, D. Chapter 1: Antimicrobial Pharmacokinetics and Pharmacodynamics. In: Gorbach S.L. and Baddour L.M. (eds) Therapy of Infectious Diseases. 2003 W.B. Saunders.
2. Andes, D., Craig, W.A. Pharmacodynamics of Fluoroquinolones. In: Hooper D.C. and Rubinstein E. (eds) 3rd Edition Quinolone Antimicrobial Agents. 2003. ASM Press Books
3. Andes, D., Craig, W.A. Treatment of Community-Acquired Respiratory
Infections with Other Antibiotics. In: File T (ed) Community Acquired Respiratory Tract Infections. Marcel Decker.
4. Andes, D. Antifungal Drug Evaluation – Candidemia Animal Models. In: Ernst EJ and Rogers PD. (eds) Methods in Molecular Medicine – Antifungal Agents. 2005 Humana Press, Totowa, New Jersey
5. Andes, D., WA Craig. Understanding Pharmacokinetics and Pharmacodynamics: Application to the Antimicrobial Formulary Decision Process. In: Owens RC, Ambrose PG, and Nightengale CH. (eds) Antibiotic Optimization Through Innovative Programs, Guidelines and Formulary Changes. 2005.
6. Andes, D., Craig W.A. Cephalosporins. In: Mandell GL, Bennett JE, and Dolin R. (eds) Principles and Practice of Infectious Diseases. 2005 Elsevier Churchill Livingstone, Philadelphia, Penn
7. O’reilly T, Andes D., Ostergaard Ch, Frimodt-Moller N. Evaluation of Antimicrobials in Experimental Animal Infections. In: Lorian V (ed). Antibiotics in Laboratory Medicine. 2005.
8. Andes D. Polyene Pharmacodynamics. In: Nightengale, Ambrose, Murakawa, Drusano (eds). Antimicrobial Pharmacodynamics in Theory and Practice. Marcel Dekker. 2005
9. Andes D. Tetracycline Pharmacodynamics. In: Nightengale, Ambrose,
Murakawa, Drusano (eds). Antimicrobial Pharmacodynamics in Theory and
Practice. Marcel Dekker. 2005
10. R. Vakil, A. Kuldipkumar, D. Andes, Y. Tan, and G. S. Kwon, Polymeric micelles for the delivery of polyene antibiotics, in S. Svenson (Ed.), Polymeric Drug Delivery Vol. I - Particulate Drug Carriers, ACS Symposium Series Vol. 923, New York, 2006, 14-26.
Abstracts
1. Andes D, Walker R, Ebert S, Craig WA. Increasing protein binding of cefonicid enhances its in-vivo activity in an animal model. 34th Interscience Conference of Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1994.
2. Craig W, Andes D, Walker R, Urban A, and Ebert S. Pharmacodynamic activities of a quinolonyl-penem carbamate in an animal infection model. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1994.
3. Walker R, Andes D, Ebert S, Conklin R, and Craig W. Pharmacodynamic comparison of 6-demethyl 6-deoxytetracyline and minocycline in an animal infection model. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1994.
4. Walker R, Andes D, Ebert S, Conklin R, and Craig W. Pharmacodynamic comparison of meropenem in an animal infection model. 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1994.
5. Andes DR, Craig WA. In-vivo activity of cefpodoxime against penicillin-resistant pneumococci. 19th International Congress of Chemotherapy, Montreal, Canada, 1995.
6. Andes D, Urban A, Craig W. Pharmacodynamics of fluoroquinolones in experimental endocarditis. Symposium on Pharmacodynamics of Antimicrobials, International Society of Antimicrobial Pharmacology, Quebec City, Quebec, Canada, 1995.
7. Andes D, Jacoby G, Craig W. Impact of extended-spectrum beta-lactamase production in K. pneumoniae on activity of four beta-lactams in an animal infection model. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology. 1995.
8. Andes D, Urban A, Craig W. In vivo activity of amoxicillin and amoxicillin/clavulanate against penicillin-resistant pneumococci. 35th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology. 1995.
9. Vesga O, Andes D, Craig W. Correlation of bacterial counts at 24 hours with survival after 4-days of therapy. 2nd International Symposium on Infection Models in Antimicrobial Chemotherapy, Rjekavik, Iceland, 1996.
10. Andes D, Vesga O, Batts D, Craig WA. Pharmacodynamic activity of a tribactam in an animal infection model. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology. 1996.
11. Andes D, Vesga O, Batts D, Craig WA. Pharmacodynamic activity of an oxazolidinone in an animal infection model. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology. 1996.
12. Vesga O, Andes D, Craig WA. In-vivo activity of synercid (RP59500) against multiple bacterial pathogens. 36th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology. 1996.
13. Vesga O, Andes D, Craig WA. In vivo pharmacodynamic activity of HMR 3004, a new ketolide. 35th Infectious Disease Society of America, 1997.
14. Vesga O, Andes D, Craig WA. Comparative in-vivo activity of HMR 3647, Azithromycin, Clarithromycin, and Roxithromycin against S. pneumoniae and S. aureus. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology. 1997.
15. Craig WA, Andes D, Vesga O. Is in-vivo activity of ketolides by bacterial counts at 24 hours predictive of survival with prolonged therapy. 4th International Conference on the Macrolides, Azalides, Streptogramins, and Ketolides, Barcelona, Spain, 1998.
16. Andes D, Vesga O, Craig WA. Impact of neutrophils on the antimicrobial activity of ketolides in an animal infection model. 4th International Conference on the Macrolides, Azalides, Streptogramins, and Ketolides, Barcelona, Spain, 1998.
17. Andes D, Van Ogtrop M, Stamsted T, Conklin B. Characterization of the in-vivo postantibiotic effects of fluconazole and flucytosine in a neutropenic murine disseminated candidiasis model. 1998 American Society for Microbiology General Meeting.
18. Van Ogtrop M.L., Andes D., Craig W.A. In vivo antimicrobial activity of MK-0826, a new carbapenem, against various penicillin-resistant pneumococci. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1998
19. Ogtrop M.L., Andes D., Craig W.A., Vesga O. In vivo activity of two glycylcyclines(GAR-936 and WAY 152,288) against tetracycline-sensitive and –resistant bacteria. 38thInterscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiolog, 1998.
20 Van Ogtrop M.L., Andes D., Craig W.A. In vivo pharmacodynamic activity
of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive
and gram negative bacteria. 38th Interscience Conference on Antimicrobial
Agents and Chemotherapy, American Society for Microbiology, 1998.
21. Van Ogtrop M.L., Andes D., Craig W.A. In vivo effect of amoxicillin/clavulanate against penicillin-resistant pneumococci simulating human pharmacokinetics. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1998.
22. Van Ogtrop M.L., Andes D., Craig W.A. In vivo activity of CS-834, a novel oral carbapenem against various penicillin-resistant pneumococci. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1998.
23. Van Ogtrop M.L., Andes D., Craig W.A. In vivo pharmacodynamic activity of CS-834, a new oral carbapenem. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1998.
24. Andes D, Van Ogtrop M, Craig W.A. Pharmacodynamic activity of a new
oxazolidinone in an animal infection model. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1998.
25. Andes D, Van Ogtrop M, Stamsted T, Conklin B. In-vivo pharmacodynamic characterization of flucytosine in a neutropenic murine disseminated candidiasis model. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology, 1998.
26. Andes D, Van Ogtrop M. In-vivo pharmacodynamic characterization of fluconazole in a neutropenic murine disseminated candidiasis model. European Society of Clinical Microbiology and Infectious Diseases, Berlin, Germany 1999.
27. Andes D. In-vivo pharmacodynamics of amphotericin B against Candida
albicans. 39th Interscience Conference on Antimicrobial Agents and
Chemotherapy, American Society for Microbiology 1999.
28. van Ogtrop ML, Andes D, Craig WA. In-vivo antimicrobial activity of MK-0826, a new carbapenem, against various gram-negative bacteria and Staphylococcus aureus. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 1999.
29. Andes D, Craig WA. In vivo pharmacodynamic activity of gemifloxacin against multiple bacterial pathogens. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 1999.
30. Andes D, Craig WA. In vivo pharmacodynamic activity of sitafloxacin against multiple bacterial pathogens. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 1999.
31. Andes D, Craig WA. In vivo pharmacodynamic activity of gatifloxacin against multiple bacterial pathogens. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 1999.
32. Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin against multiple bacterial pathogens. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology
1999.
33. Andes D, Craig WA. Pharmacodynamics of gemifloxacin against quinolone-resistant strains of Streptococcus pneumoniae with known resistance mechanisms. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 1999.
34. Andes D, Craig WA. Impact of Neutrophils on the In-vivo Activity of
Fluoroquinolones. 37th Infectious Diseases Society of America 1999.
35. Safdar N, Andes D, Craig WA. In-vivo pharmacodynamic characterization of daptomycin. 37th Infectious Diseases Society of America 1999.
36. Andes DR, Craig WA. In-vivo pharmacodynamics of RO-63-9141 against
multiple bacterial pathogens. 40th Interscience Conference on Antimicrobial
Agents and Chemotherapy, American Society for Microbiology 2000.
37. Andes DR, Craig WA. In-vivo pharmacodynamics of ABT-773, a new ketolide antibiotic. 40th Interscience Conference on Antimicrobial Agents and
Chemotherapy, American Society for Microbiology 2000.
38. Craig WA, Andes DR. Impact of macrolide resistance on the in-vivo activity of ABT-773 on Streptococcus pneumoniae. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology
2000.
39. Craig WA, Andes DR. In-vivo pharmacodynamic activity of cefditoren against Streptococcus pneumoniae. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2000.
40. Andes D, Stamstad T, Conklin R. In-vivo Characterization of the Pharmacodynamics of Ravuconazole (BMS 207147) in a Neutropenic Murine
Disseminated Candidiasis Model. 40th Interscience Conference on Antimicrobial
Agents and Chemotherapy, American Society for Microbiology 2000.
41. Andes D, Weisblum B. In-vitro Characterization of the Pharmacodynamics of Ergosterol Gene Expression in S. cerevisiae Following Fluconazole Exposures 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2000.
42. Craig WA, Andes D. Correlation of the magnitude of the AUC/MIC for 6 fluoroquinolones against Streptococcus pneumoniae with survival and bactericidal activity in an animal model. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2000.
43. Andes, D., Craig WA. Differences in the in vivo pharmacodynamics of telithromycin and azithromycin against Streptococcus pneumoniae. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2000.
44. WA Craig and D. Andes. Pattern of bactericidal activity of telithromycin against erythromycin-resistant Streptococci pneumoniae in the murine thigh-infection model. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
45. D. Andes, K. Marchillo, R. Conklin, T. Stamsted. Correlation of the ravuconazole AUC/MIC ratio associated with efficacy against 8 Candida albicans strains in a neutropenic murine model. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
46. D. Andes, J. Lowther, A. Bryskier, K. Marchillo. In-vivo characterization of the pharmacodynamics of HRM 3270, a new lipopeptide, in a murine candidiasis model. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
47. J. Christianson, D. Andes, WA Craig. Characterization of the pharmacodynamics of doxycycline against Streptococcus pneumoniae in a murine thigh-infection model. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
48. J. Christianson, D. Andes, WA Craig. Characterization of the pharmacodynamics of clindamycin against Streptococcus pneumoniae in a murine thigh-infection model. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
49. Christianson J, D. Andes, W. Craig. Magnitude of the 24-h AUC/MIC required for efficacy of doxycycline against Streptococcus pneumoniae in a murine thigh infection model. 39th Infectious Diseases Society of America, 2001
50. WA Craig, D. Andes. In vivo pharmacodynamics of BB-83698, a deformylase inhibitor. Christianson, D. Andes, WA Craig. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
51. S. Wang, D. Andes, W. Craig. Pharmacodynamics of nafcillin, vancomycin, linezolid, daptomycin, alone and in combination of NAF + VAN and NAF + LIN against MSSA and MRSA in a murine thigh-infection model. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
52. D. Andes, WA Craig. Impact of extended-spectrum beta-lactamase (ESBL) production on the activity of cefepime in a murine-thigh infection model. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
53. WA Craig, D. Andes. Activity of clarithromycin against susceptible and resistant S. pneumoniae in murine thigh and lung infection models. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
54. WA Craig, D. Andes. In vivo pharmacodynamics of PGE-9509924, a new non-fluorinated quinolone. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
55. WA Craig, D. Andes. In vivo pharmacodynamic activity of ceftriaxone against viridans streptococci: implications for susceptibility breakpoints. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
56. WA Craig, D. Andes. Pharmacodynamic characterization of AZD2563, the new oxazolidinone, in a murine thigh-infection model. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
57. Wang S, Andes DR, Craig WA: Pharmacodynamics of nafcillin (NAF), vancomycin (VAN), linezolid (LIN), daptomycin (DAP), alone and combination of NAF+VAN and NAF+LIN against MSSA and MRSA in murine thigh infection model. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001.
58. DR Andes, WA Craig. In vivo pharmacodynamic activity of AZD2563, the new oxazolidinone against multiple bacterial pathogens. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
59. Craig W.A., Andes D.R. In vivo pharmacodynamic activity of faropenem against Streptococcus pneumoniae. 41th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2001.
60. M. Adams, D. Andes, G. Kwon. A Novel and Effective Polymeric Micelle Formulation of Amphotericin B. 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2002.
61. D. Andes, K. Marchillo, R. Conklin. In-vivo Characterization of the Pharmacodynamics (PD) of the New Triazole, Posaconazole (POS) , in a Murine Candidiasis Model 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2002
62. D. Andes, K. Marchillo, R. Conklin. Amphotericin B (AmB) and Liposomal AmB (L-AmB) in a Candidiasis Model. 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2002
63. Christianson JC, WA Craig, S. Kiem, DR Andes. Impact of neutrophils on pharmacodynamic activity of clindamycin and doxycycline against Streptococcus pneumoniae. 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2002
64. WA Craig, S. Kiem, DR Andes. Free drug 24 hr AUC/MIC is the PK/PD target that correlates with in vivo efficacy of macrolides, azalides, ketolides and clindamycin. 42th Interscience Conference on Antimicrobial Agents and Chemotherapy, American Society for Microbiology 2002
65. W Karchmer, P. Pappas, R. Merion, G. Cloud, S. Hadley, J. Rabkin, D. Andes, C. Kauffman, J. Daly, S. Kusne, B. Alexander and MSG Study #44 NIAID. Invasive Fungal Infection in Liver Transplant Recipients Considered at Low Risk.40th Annual Meeting of the Infectious Diseases Society of America. 2002
66. Christianson J. and Andes D. Primary Cutaneous Cryptococcosis: Case
Report and Literature Review. 40th Infectious Diseases Society of America
Annual Meeting. 2002
67. N. Safdar, V. Knasinski, D. Andes. Characterization of Candiduria in RenalTransplant Recipients. 15th Congress of the International Society for Human and Animal Mycology (ISHAM), 2003.
68. D. Andes, K. Marchillo. Pharmacodynamics of the emergence of fluconazole resistance in Candida albicans. 15th Congress of the International Society for Human and Animal Mycology (ISHAM), 2003.
69. N. Safdar, V. Knasinski, D. Andes. Epidemiology of Candiduria in Renal Transplant Recipients. 13th Annual Society for Health Care Epidemiology, 2003.
70. G.S. Kwon, A. Kuldipkumar, Y. Tan, D. Andes. Polymeric micelles for the
delivery of polyene antibiotics. Abstract 33. 226th American Chemical Society National Meeting 2003.
71. D. Andes, WA Craig. In vivo pharmacodynamic activity of garenoxacin against multiple bacteria in a murine thigh infection model. 43th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003
72. D. Andes, K. Marchillo, R. Conklin. In vivo pharmacodynamics of voriconazole against C. albicans. 43th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003
73. D. Andes, A. Lepak, A. Pitula, J. Smith. Pharmacodynamic regulation of drug-resistance in C. albicans. 43th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003
74. D. Andes, S. Kiem, WA Craig. In vivo pharmacodynamics of doripenem against multiple bacteria in a murein thigh infection model. 43th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003
75. S. Kiem, D. Andes, WA Craig. The Effect of Protein Binding on the Antimicrobial Activity of Daptomycin in Sera and Albumin Solution. 43th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003
76. Pappas PG, J. Morgan, RA Hajjeh, and the Transplant Associated Infection Surveillance Network. Prospective surveillance for invasive fungal infections in hematopoetic stem cell and solid organ transplant recipients. 43th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003
77. D. Andes, A. Lepak. Relationship Between Fluconazole Pharmacodynamic (PD) Exposure In Vitro and S. cerevisiae Genome Expression. 43th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003
78. D. Andes, N. Safdar, K. Marchillo, R. Conklin. In vivo Pharmacokinetic (PK) and Pharmacodynamic (PD) Comparison of Amphotericin B (AmB), Liposomal Amphotericin (L-AmB), and ABLC in Various Organs against C. albicans. 43th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003
79. WA Craig, S. Kiem, D. Andes, P. Ambrose, R. Jones. Impact of ESBLs
on in vivo activity of four cephalosporins in the neutropenic mouse-thigh infection
model. 43rd Interscience onference on Antimicrobial Agents and Chemotherapy, 2003
80. D. Andes, W.A. Craig, S.M. Bhavnani R.N. Jones, D. Thye, M.A. Wikler, P.G. Ambrose. PK-PD Evaluation of Doripenem (DOR) Against Extended Spectrum ß-Lactamase (ESBL) Producing Enterobacteraceae. 41st Infectious Diseases Society of America, 2003.
81. W. Slattery, N. Safdar, V. Knasinski, DR Andes. Case-Control Analysis of Risk Factors For Candiduria in Renal Transplant Recipients. 41st Infectious Diseases Society of America, 2003.
82. G. Gauthier, D. Andes, N. Safdar. The epidemiology of Blastomycosis in solid organ transplant recipients. 41st Infectious Diseases Society of America, 2003.
83. D. Andes, A. Lepak, K. Marchillo, A. Pitula. Impact of fluconazole postantifungal effect on mRNA abundance of CDR1 and CDR2 efflux pumps in a murine infection model. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004
84. D. Andes, K. Marchillo, J. Nett, A. Pitula, J. Smith. Flucoonazole pharmacodynamics and the emergence of Candida albicans resistance in an in vivo infection model. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004
85. D. Andes, WA Craig. In vivo pharmacodynamic activity of PPI-0903, a new cephalosporin against multiple bacteria in murine lung and thigh infection models. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004
86. D. Andes, WA Craig. In vivo pharmacodynamic characterization of dalbavancin in the murine thigh infection model. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004
87. D. Andes, WA Craig. In vivo determination of the magnitude of the dalbavancin pharmacodynamic parameter associated with efficacy against multiple bacteria in a murine infection model. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004
88. CR Rayner, D. Andes, T. Stamstad, K. Marchillo, B. Conklin, WA Craig. Comparison of Fluoroquinolone (FQ) Dose effect Relations by Interval & FQ against Pseudomonas aeruginosa ATCC 27853 (PSA) in Neutropenic Murine-Thigh Infection Models. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004
89. D. Andes, N. Safdar, P. Pappas, C. Kauffman, B. Alexander and CDC TRANSNET Group. Multi-center epidemiology of Candida infections in Solid and Liquid Transplant Patients. 42nd Infectious Diseases Society of America, 2004.
90. N. Safdar, D. Andes, P. Pappas, C. Kauffman, B. Alexander and CDC TRANSNET Group. Comparative Risk of C. albcians and Non-albicans Infections in Solid and Liquid Transplant, A Multicenter Study.Patients. Infectious Diseases Society of America 2004.
91. J. Smith, N. Safdar, V. Knasinski, D. Andes. Voriconazole (V) Therapeutic Drug Monitoring (TDM) : Indications, Levels, and Outcome at a Single Tertiary Care Hospital. 42nd Infectious Diseases Society of America, 2004.
92. J. Smith, N. Safdar, V. Knasinski, D. Andes. Osteomyelitis in Organ Transplantation: Epidemiology and Outcome. 42nd Infectious Diseases Society of America, 2004.
93. Craig WA, Kiem S, Andes DR. Effect of protein binding on the antimicrobial activity of daptomycin in sera and albumin solution. 42nd Infectious Diseases Society of America, 2004.
.
94. Baddley JW, B Park, K Marr, D Andes, D Kontoyiannis, S Hadley, M
Schuster, Oster, B Alexander, T Walsh, Pappas. Factors influencing outcome
in transplant recipients with invasive aspergillosis. 44th Interscience Conference
on Antimicrobial Agents and Chemotherapy. 2004.
95. Craig W, Andes D. Activity of Oritavancin (O) versus Vancomycin (V) in the Neutropenic Murine Thigh- and Lung-Infection Models. Presented at the 44th
Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004.
96. Craig W, D. Andes. In vivo pharmacodynamics of NVP-PDF-713, a new peptide deformylase inhibitor. European Congress of Chemotherapy Microbiology Infectious Diseases, Prague, Czech., 2004
97. Craig W, D. Andes. In vivo pharmacodynamics of NVP-PDF-713, a new peptide deformylase inhibitor against multiple bacterial pathogens. European Congress of Chemotherapy Microbiology Infectious Diseases, Prague, Czech., 2004
98. V. Morrison, D. Andes, S. Hadley, M Schuster, C Kauffman, P Pappas and TRANSNET. The spectrum of non-albicans candidal infections in stem cell and solid organ transplant recipients: a prospective evaluation. 44th Interscience
Conference on Antimicrobial Agents and Chemotherapy. 2004.
99. D Tsitsigiannis, JW Bok, T Hammond, DW Chung, D Andes, J Frisvad, N
Keller. Increased virulence in Aspergillus fumigatus prostaglandin mutants.
2004 Fungal Gordon Conference.
100. S. Hadley, A Friefeld, D Andes, L Herwaldt, C Kauffman, M Schuster, S Fridkin, P Pappas, and TRANSET Investigators. Endemic mycoses and Cryptococcus infections among transplant recipients reporting to TRANSNET. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004.
101. Juliette Morgan, Kathleen A. Wannemuehler, Scott K. Fridkin, Peter G. Pappas and David W. Warnock for the TransNet Surveillance Investigators. Is the incidence of aspergillosis underestimated? Advances in Aspergillosis 2004
102. Balajee SA, Bok JW, Marr KA, Andes D, Nielsen KF, Frisad J, Gribskov J, Keller NP. LaeA, a virulence determinant in Aspergillus fumigatus. Advances in
Aspergillosis 2004.
103. Ambrose PG, Phillips L, Bhavnani SM, Van Wart SA, Cirincione B, Andes D, Wikler A. Use of pharmacokinetics-pharmacodynamics as decision support for phase 3 dose justification for doripenem. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004.
104. Pare’ JA, Andes D, Sigler L. In vitro susceptibility of fungal isolates from reptiles to antifungal drugs. 2005 American Association of Zoo Veterinarians (AAZV) Annual Meeting, Omaha, Nebraska.
105. D. Andes, N Safdar, B Alexander, S Fridkin, S Hadley, , C Kauffman, L
Brumble, R Walker, M Schuster, A Freifeld, P Pappas and TRANSNET
Investigators Comparative Epidemiology of Invasive Candida (IC) Infections
Among Organ Transplant Recipients (OTRs): Prospective Surveillance Results
from the CDC TRANSNET Database. 43rd Infectious Diseases Society of
America, 2005
106. J. Smith, N. Safdar, V. Knaskinski, W. Simmons, D. Andes. Infectious
Complications Associated with Alemtuzumab (Campath = anti-CD52) in Solid
Organ Transplant Recipients: A Retrospective Cohort Study. 43rd Infectious
Diseases Society of America, 2005
107. D. Andes, J Lowther, WA Craig. In vivo Determination of the Magnitude of
the Pharmacodynamic Parameter Associated with Efficacy for the Streptogramin,
XRP 2868, Against Multiple Bacteria in a Murine Infection Model. 45th
Interscience Conference on Antimicrobial Agents and Chemotherapy, 2005
108. D. Andes, J Lowther, WA Craig. In vivo Determination of the Magnitude of
the Pharmacodynamic Parameter Associated with Efficacy for the
Topoisomerase Inhibitor, AVE 6971, Against Multiple Bacteria in a Murine
Infection Model. 45th Interscience Conference on Antimicrobial Agents and
Chemotherapy, 2005
109. W.A. Craig, D.R. Andes. In Vivo Evaluation of Pulsatile Delivery of
Amoxicillin against Strains of Streptococcus pneumoniae with Normal and
Reduced Susceptibility 45th Interscience Conference on Antimicrobial Agents
and Chemotherapy, 2005
110. W.A. Craig, D. Andes, K.L. LaPlante, M.J. Rybak. In Vivo Activity of
Clindamycin (CLIN), Daptomycin (DAP), Doxycycline (DOXY), and Linezolid
(LND) against Clindamycin Inducible-Resistance (CIR) Community-Associated
Methicillin-Resistant Staphylococcus aureus (CA-MRSA) in a Murine Thigh-
Infection Model 45th Interscience Conference on Antimicrobial Agents and
Chemotherapy, 2005
111. W.A. Craig, D.R. Andes, P.G. Ambrose, R.G. Jones. In-Vivo
Pharmacodynamic Activity of Gatifloxacin (GATI), Levofloxacin (LEVO), and
Moxifloxacin (MOXI) Against Staphylococcus aureus with Reduced Susceptibility
to Fluoroquinolones (FQs). 45th Interscience Conference on Antimicrobial Agents
and Chemotherapy, 2005
112. W.A. Craig, D.R. Andes, M. Dudley, G.H. Miller. In Vivo Activity of BP-
102, A New Carbacephem, Against Methicillin-Susceptible and -Resistant
Strains of Staphylococcus aureus (MSSA and MRSA) in the Thighs of
Neutropenic Mice 45th Interscience Conference on Antimicrobial Agents and
Chemotherapy, 2005
113. D. Andes, A. Forrest. Mathematical Modeling of In vivo C. albicans
Resistance Emergence Related to Fluconazole(F) Pharmacodynamics (PD).
45th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2005
114. A. Lepak, D. Andes. C. albicans Global Transcriptional Profile During and
Following Fluconazole (F) Exposure – Gene Expression PAE. 45th Interscience
Conference on Antimicrobial Agents and Chemotherapy, 2005
115. Hadley S, Pappas P, Lyon M, Alexander B, Kauffman C, Andes D,
Freifeld A, Fan K, Morgan J. Cryptococcus neoformans infections among solid
organ transplant recipients reporting to TRANSNET. 43rd Infectious Diseases
Society of America, 2005
116. Freifeld A, Kauffman C, Pappas PG, Walker R, Andes D, Hadley S, Fan
K, Morgan J. Endemic fungal infections among solid organ transplant recipients.
43rd Infectious Diseases Society of America, 2005
117. Nett J, L. Lincoln, M. Van Handel, D. Andes. Comparison of cell wall and
secreted glucan in C. albicans biofilm and planktonic cells. Candida and
Candidiasis, American Society for Microbiology, 2006
118. Lincoln L, Nett J, Lepak A, M. Van Handel, D. Andes. Analysis of the
global transcriptional profile of C. albicans cells from an in vivo catheter biofilm
model. Candida and Candidiasis, American Society for Microbiology, 2006
119. Nobile CJ, Andes D, Nett J, Filler S, Mitchell AP. The Candida albicans
transcription factor Bcr1p governs biofilm development in vitro and in vivo by
activation of ALS3. Candida and Candidiasis, American Society for
Microbiology, 2006
120. Safdar N, Smith J, Knasinski V, Andes D. Infectious Complications
Associated with Alemtuzumab (Campath = anti-CD52) in Solid Organ Transplant
Recipients: A Case Controlled Study. 44th Infectious Diseases Society of
America, 2006
121. Nett J, Lincoln L, Marchillo K, Andes D. Measurement of Beta 1,3 glucan
for Diagnosis of C. albicans Biofilms In vitro and In vivo. 44th Infectious Diseases
Society of America, 2006
122. Andes D., Marchillo K. In-vivo Pharmacodynamic Characterization of a
New Echinocandin, Anidulafungin, Against Candida albicans and Candida
glabrata in the Neutropenic Murine Disseminated Candidiasis Model 46th
Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006
123. Andes D., Craig WA. In-vivo Pharmacodynamic Activity of a New
Carbapenem, SMP 601, Against Multiple Bacteria in Murine Thigh and Lung
Infection Models. 46th Interscience Conference on Antimicrobial Agents and
Chemotherapy, 2006
124. Nett J., Lincoln L, Marchillo K, Wong J., Andes D. Impact of Beta 1,3
Glucanase on Antifungal Activity Against C. albicans in Biofilms In vitro and In vivo. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006
125. Freifeld A, Proia L, Andes D, Baddour LM, Blair J, Spellberg B, Arnold S,
Lentnek A, Wheat J. Voriconazole (vori) Use for Endemic Fungal Infections
(EFI) 44th Infectious Diseases Society of America, 2006
126. Baddley J, Andes D. Predictive Value of Fluconazole (F)
Pharmacodynamics (PD) in Candidemia: A Single Center Prospective Case
Series. 44th Infectious Diseases Society of America, 2006
127. Craig WA, Andes D. Impact of neutrophils and the site of infection on the in vivo pharmacodynamics of MX-2401 against S. pneumoniae in thigh and lung infections in neutropenic and normal mice. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006
128. Craig WA, Andes D, Paterson D. In vivo activity of levofloxacin against Salmonella species susceptible and resistant to naldixic acid in the neutropenic murine thigh infection model. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006
129. Andes D, Craig WA, Odinecs A. In vivo pharmacodynamics of MX-2764/PTK-0796 against various gram-positive and gram-negative bacteria in the thighs of neutropenic and normal mice. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006
130. Craig WA, Andes D. In vivo pharmacodynamics of vancomycin against VISA, heteroresistant VISA and VSSA in the neutropenic murine thigh infection model. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006
.
131. Craig WA, Andes D, Pasetka C, Erfle DJ. In vivo pharmacodynamics of MX-2401 against S. aureus and S. pneumoniae in thigh infections in neutropenic mice. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2006
132. Baddley JW, Kano R, Brandt ME, Marr KA, Kauffman CA, Andes DR, Moser SA, Pappas PG, Balajee SA. Molecular characterization and antifungal susceptibilities of aspergilli from the TRANSNET. ICAAC 2007
133. J.W. Baddley1,2 , D.R. Andes3, E.J. Anaissie4, R.A. Oster1 C.A. Kauffman5,6, A. Freifeld7, T. M. Perl5, J. Ito8, P. G. Pappas Factors Associated with Mortality in Transplant Patients with Candidemia: Results from the Transplant Associated Infection Surveillance Network (TRANSNET) IDSA 2007
134. J.W. Baddley1, K.A. Marr2, D.R. Andes3, D.P Kontoyiannis4, T.F. Patterson5, E.J. Annaissie6, T.J.Walsh7, B.D. Alexander8, M.Schuster9, R.A. Oster1, and P. G. Pappas Epidemiology of Aspergillus terreus Infection in Transplant Recipients from Transplant Associated Infection Surveillance Network (TRANSNET)
IDSA 2007
136. Nett J, Vujnovich K, Holoyda K, Hichwa M, Marchillo K, Andes D. Impact of Common Disinfectants on Candida Biofilms Interscience Conference on Antimicrobial Agents and Chemotherapy 2007.
137. thington-Skaggs1, N Iqbal1, BJ Park1, C Kauffman2, S Hadley3, L Brumble4, D Andes5, J Ito6, T. Chiller1, P Pappas7, and the TRANSNET investigators In Vitro Susceptibility of Candida spp. From Proven Cases of Invasive Candidiasis (IC) in Solid Organ and Stem Cell Transplant Recipients: TRANSNET 2001-2006 ICAAC 2007
138. Ostrosky-Zeichner L, Andes D A proposal for an antifungal susceptibility testing (AST) breakpoint for Micafungin (MFG) and Candida spp.: Integration of population-based surveys and correlation with outcomes from clinical trials.
ICAAC 2007
139. Bhavnani, SM, Okusanya OO, Hammel JP., Forrest A, Drusano, GL, Andes D, Craig WA, Pace JL, Young CL, Xerri L, Ambrose PG. Population pharmacokinetic and monte carlo simulation analyses to support phase 2/3 PZ-601 dosing strategies for complicated skin and skin structure infections. Interscience Conference on Antimicrobial Agents and Chemotherapy 2007.
140. Forrest A, Rubino CM, Craig WA, Andes DR, Sorgel F, Bhavnani SM, Kinzig-Schippers M, Rodamer M, Jones RN, Ambrose PG. Use of pharmacokinetics-pharmacodynamics and monte carlo simulations as decision support for determination of penicillin VK susceptibility breakpoints for Streptococcus pneumoniae. Interscience Conference on Antimicrobial Agents and Chemotherapy 2007.
B3. Invited Research Presentations
Years Location Title
UNIVERSITY OF WISONSIN
2001 Pharmaceutical Sciences Seminar Antimicrobial Pharmacodynamics and Drug Resistance
2003 Medical Microbiology and Immunology Research Seminar Resistance in Candida albicans:
Pharmacodynamic and In vivo
Considerations
2004 Meeting Co-Chair Fungal Disease – Bridging the Gap Between the Bench and Bedside
NATIONAL
1998 International Society of Antimicrobial Pharmacology Pharmacodynamics of Antifungals
2001 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Use of pharmacodynamics as an
alternative for human trials in the
evaluation of antifungals?
2001 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Session Chair – Topics in Pharmacokinetics and Pharmacodynamics
2002 Infectious Disease Society of America – 2002 Annual Meeting Clinical Impact of Antibacterial and Antifungal Pharmacodynamics
2002 University of Missouri School of Medicine – Alumni Lecture Advances in Anti-Infective Therapy
2003 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy Clinical relevance of antifungal pharmacokinetics and pharmacodynamics
2003 International Forum on
Antibiotic Resistance
Colloquium Outcomes, Resistance and Regulation Animal Models: Improving prediction and performance with PK/PD studies
2004 Workshop on Animal Models of Infection – Novartis Pharmacodynamic Characterization of Antimicrobials In vivo
2004 Antifungal Workshop – University of Texas Pediatric Pharmacology Antifungal Pharmacodynamics
2004 44th Interscience Conference on Antimicrobial Agents and Chemotherapy Deep Infections in the eye, brain, and
bone – Tissue penetration of antifungal drugs
2004 FDA Workshop – Antimicrobial Development Use of Animal Model PK/PD for Dose Selection
2004 44th Interscience Conference on Antimicrobial Agents and Chemotherapy Clinical Relevance of Pharmacokinetics and Pharmacodynamics on Anti-Infective Agents
2005 International
Immunocompromised Host
Society – Fungal Infections In Solid Organ Transplant Epidemiology and Risk Factors for Invasive Fungal Infections In Solid Organ Transplantation
2005 Merck Research Symposium Use of Animal Model Pharmacodynamics in Antimicrobial Drug Development
2005 105th American Society for Microbiology General Meeting Use of Animal Models of Fungal Infection in Drug Development
2005 45th Interscience Conference on Antimicrobial Agents and Chemotherapy Application of Preclnical Pharmacokinetics and Pharmacodynamics in Drug Development
2005 Pediatric Infectious Disease Roundtable Treatment of Infection Due to ESBL Producing Organisms – What Really Matters?
2005 University of Alabama – Birmingham, Transplant Grand Rounds Fungal Infections in Solid Organ Transplant
|